Harvard Bioscience Stock
Price
Target price
€0.34
€0.34
3.030%
0.01
3.030%
-
02.10.25 / Frankfurt
WKN: 578107 / Symbol: HBIO / Name: Harvard / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Harvard Bioscience Stock
A very strong showing by Harvard Bioscience today, with an increase of €0.010 (3.030%) compared to yesterday's price.
So far the community has only identified positive things for Harvard Bioscience stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Harvard Bioscience in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Harvard Bioscience vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Harvard Bioscience | 3.030% | -2.941% | -13.613% | -85.268% | -82.162% | -88.043% | -86.905% |
| MicroVision Inc | 5.880% | 3.376% | 15.808% | 8.042% | -25.833% | -69.782% | -35.820% |
| Fonar Corp. New | 7.810% | -0.775% | -5.185% | -9.220% | -9.859% | -8.571% | -29.670% |
| Fluidigm Corp. | 0.000% | -2.727% | 3.883% | -34.356% | -37.427% | -2.194% | -83.944% |
Comments
Harvard Bioscience, Inc. (NASDAQ: HBIO) had its price target raised by analysts at Benchmark Co. from $3.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HBIO provided by MarketBeat
News
Investing in Nuclear Power? I Like Nuscale Power Stock, Up 213% in 2025
So far this year, NuScale Power (NYSE: SMR) stock has more than tripled in value. The reason: rapidly rising interest in small-scale nuclear power. NuScale is arguably the leading developer of small
Harvard Bioscience Tops Q2 Revenue Views
Harvard Bioscience (NASDAQ:HBIO), a provider of specialized laboratory technologies for biomedical and life sciences research, released its financial results for the second quarter of fiscal 2025 on
3 Top Dividend Stocks Analysts Are Bullish on Right Now
We’re at the end of earnings season. That means it’s time for analysts to weigh in on the outlook for specific stocks. While there’s cautious optimism about how the second half of the year will
